Biological immunotherapy for lung cancer currently refers to the use of two immune checkpoint inhibitors, pablizumab and nivolumab. The cost of these two immune checkpoint inhibitors is currently around $20,000-30,000 per month. It is worth noting that these immune checkpoint inhibitors may sometimes be used alone, for example, in advanced non-small cell lung cancer, if PD-1 or PD-L1 is found to be greater than or equal to 50%, then pabolizumab can be used alone in the first line, and the cost is what was mentioned earlier, while if the expression of PD-1 or PD-L1 is less than 50%, then it may need to be combined with chemotherapy, or If the expression of PD-1 or PD-L1 is less than 50%, then it may be necessary to combine chemotherapy or anti-tumor angiogenesis drugs together, and the cost of bioimmunotherapy will be increased by about 5000-10000 RMB.